peri-menopause

Patients

One of the biggest challenges for women in their 40s and 50s going through the menopause is the recognition that one size does not fit all.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.